Lidbree (Lidocaine)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium that initiates an action potential. This stabilises the neuronal membrane, halting the transmission of pain signals from the treated area and producing a reversible loss of sensation.

The specific dose of Lidbree is determined by the prescribing clinician based on the procedure, patient characteristics, and clinical guidelines. Healthcare professionals calculate the appropriate volume and concentration to achieve effective uterine anesthesia while minimizing systemic exposure.

Safety data for intrauterine lidocaine during pregnancy and lactation are limited. It should only be used when the expected benefit justifies any potential risk to the mother or fetus. Clinicians should evaluate each case individually and follow local regulatory recommendations.

To request Lidbree, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Lidbree contains lidocaine, an amide‑type local anesthetic with a rapid onset and moderate duration of action. Compared with ester‑type agents, lidocaine generally offers a lower risk of allergic reactions and predictable metabolism. Choice of agent depends on clinician preference, procedural requirements, and patient-specific factors.

Lidbree should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the solution, and inspect the vial for any particulate matter before use.

Lidbree is administered by a qualified healthcare professional directly into the uterine cavity using a sterile applicator or catheter. The volume injected is calculated to achieve adequate local anesthesia while avoiding systemic absorption. Standard aseptic technique and patient monitoring are recommended throughout the procedure.

Serious risks include allergic reactions such as anaphylaxis, cardiovascular toxicity (e.g., arrhythmias, severe hypotension), central nervous system toxicity (e.g., seizures, altered consciousness), and rare cases of methemoglobinemia. Prompt recognition and supportive management are essential if any of these events occur.

Lidbree should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe hepatic impairment, and individuals with significant cardiac conduction disorders unless the benefits clearly outweigh the risks. Consultation with a specialist is advised for high‑risk patients.